PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
SYRE vs. RXT
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between SYRE and RXT is 0.17, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.2

Performance

SYRE vs. RXT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Spyre Therapeutics Inc. (SYRE) and Rackspace Technology, Inc. (RXT). The values are adjusted to include any dividend payments, if applicable.

-20.00%0.00%20.00%40.00%SeptemberOctoberNovemberDecember2025February
-14.58%
33.98%
SYRE
RXT

Key characteristics

Sharpe Ratio

SYRE:

0.01

RXT:

0.83

Sortino Ratio

SYRE:

0.52

RXT:

1.49

Omega Ratio

SYRE:

1.06

RXT:

1.19

Calmar Ratio

SYRE:

0.01

RXT:

0.65

Martin Ratio

SYRE:

0.02

RXT:

3.34

Ulcer Index

SYRE:

34.84%

RXT:

18.23%

Daily Std Dev

SYRE:

71.34%

RXT:

73.26%

Max Drawdown

SYRE:

-99.12%

RXT:

-95.86%

Current Drawdown

SYRE:

-92.43%

RXT:

-88.65%

Fundamentals

Market Cap

SYRE:

$1.34B

RXT:

$657.67M

EPS

SYRE:

-$37.90

RXT:

-$3.45

Total Revenue (TTM)

SYRE:

$0.00

RXT:

$2.05B

EBITDA (TTM)

SYRE:

-$147.31M

RXT:

-$441.50M

Returns By Period

In the year-to-date period, SYRE achieves a -2.58% return, which is significantly lower than RXT's 33.94% return.


SYRE

YTD

-2.58%

1M

9.04%

6M

-14.58%

1Y

0.62%

5Y*

-35.63%

10Y*

N/A

RXT

YTD

33.94%

1M

25.69%

6M

33.94%

1Y

63.54%

5Y*

N/A

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

SYRE vs. RXT — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SYRE
The Risk-Adjusted Performance Rank of SYRE is 4545
Overall Rank
The Sharpe Ratio Rank of SYRE is 4545
Sharpe Ratio Rank
The Sortino Ratio Rank of SYRE is 4545
Sortino Ratio Rank
The Omega Ratio Rank of SYRE is 4545
Omega Ratio Rank
The Calmar Ratio Rank of SYRE is 4545
Calmar Ratio Rank
The Martin Ratio Rank of SYRE is 4646
Martin Ratio Rank

RXT
The Risk-Adjusted Performance Rank of RXT is 7171
Overall Rank
The Sharpe Ratio Rank of RXT is 7373
Sharpe Ratio Rank
The Sortino Ratio Rank of RXT is 7070
Sortino Ratio Rank
The Omega Ratio Rank of RXT is 6969
Omega Ratio Rank
The Calmar Ratio Rank of RXT is 7171
Calmar Ratio Rank
The Martin Ratio Rank of RXT is 7474
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

SYRE vs. RXT - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Spyre Therapeutics Inc. (SYRE) and Rackspace Technology, Inc. (RXT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for SYRE, currently valued at 0.01, compared to the broader market-2.000.002.004.000.010.83
The chart of Sortino ratio for SYRE, currently valued at 0.52, compared to the broader market-6.00-4.00-2.000.002.004.006.000.521.49
The chart of Omega ratio for SYRE, currently valued at 1.06, compared to the broader market0.501.001.502.001.061.19
The chart of Calmar ratio for SYRE, currently valued at 0.01, compared to the broader market0.002.004.006.000.010.65
The chart of Martin ratio for SYRE, currently valued at 0.02, compared to the broader market0.0010.0020.0030.000.023.34
SYRE
RXT

The current SYRE Sharpe Ratio is 0.01, which is lower than the RXT Sharpe Ratio of 0.83. The chart below compares the historical Sharpe Ratios of SYRE and RXT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio0.001.002.003.004.00SeptemberOctoberNovemberDecember2025February
0.01
0.83
SYRE
RXT

Dividends

SYRE vs. RXT - Dividend Comparison

Neither SYRE nor RXT has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

SYRE vs. RXT - Drawdown Comparison

The maximum SYRE drawdown since its inception was -99.12%, roughly equal to the maximum RXT drawdown of -95.86%. Use the drawdown chart below to compare losses from any high point for SYRE and RXT. For additional features, visit the drawdowns tool.


-92.00%-90.00%-88.00%-86.00%-84.00%SeptemberOctoberNovemberDecember2025February
-90.77%
-88.65%
SYRE
RXT

Volatility

SYRE vs. RXT - Volatility Comparison

The current volatility for Spyre Therapeutics Inc. (SYRE) is 15.63%, while Rackspace Technology, Inc. (RXT) has a volatility of 19.19%. This indicates that SYRE experiences smaller price fluctuations and is considered to be less risky than RXT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


15.00%20.00%25.00%30.00%SeptemberOctoberNovemberDecember2025February
15.63%
19.19%
SYRE
RXT

Financials

SYRE vs. RXT - Financials Comparison

This section allows you to compare key financial metrics between Spyre Therapeutics Inc. and Rackspace Technology, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab